HRS 5965
Alternative Names: HRS-5965Latest Information Update: 30 Oct 2024
At a glance
- Originator Chengdu Suncadia Medicine
- Class Anti-inflammatories; Urologics
- Mechanism of Action Complement factor B modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Paroxysmal nocturnal haemoglobinuria
- Phase I Glomerulonephritis
Most Recent Events
- 08 Oct 2024 Chengdu Suncadia Medicine completes a phase I trial (In volunteers) in China (PO) (NCT06567392)
- 19 Sep 2024 Chengdu Suncadia Medicine plans a phase III trial for Paroxysmal Nocturnal Hemoglobinuria in China (PO, Capsule), in September 2024 (NCT06593938)
- 03 Sep 2024 Chengdu Suncadia Medicine initiates a phase I trial (In volunteers) in China (PO) (NCT06567392)